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Abstract: Marine sponges are currently one of the richest sources of pharmacologically 
active compounds found in the marine environment. These bioactive molecules are often 
secondary  metabolites,  whose  main  function  is  to  enable  and/or  modulate  cellular 
communication and defense. They are usually produced by functional enzyme clusters in 
sponges  and/or  their  associated  symbiotic  microorganisms.  Natural  product  lead 
compounds from sponges have often been found to be promising pharmaceutical agents. 
Several of them have successfully been approved as antiviral agents for clinical use or have 
been advanced to the late stages of clinical trials. Most of these drugs are used for the 
treatment of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). The 
most  important  antiviral  lead  of  marine  origin  reported  thus  far  is  nucleoside  Ara-A 
(vidarabine) isolated from sponge Tethya crypta. It inhibits viral DNA polymerase and 
DNA  synthesis  of  herpes,  vaccinica  and  varicella  zoster  viruses.  However  due  to  the 
discovery of new types of viruses and emergence of drug resistant strains, it is necessary to 
develop new antiviral lead compounds continuously. Several sponge derived antiviral lead 
compounds which are hopedto be developed as future drugs are discussed in this review. 
Supply problems are usually the major bottleneck to the development of these compounds 
as drugs during clinical trials. However advances in the field of metagenomics and high 
throughput microbial cultivation has raised the possibility that these techniques could lead 
to  the  cost-effective  large  scale  production  of  such  compounds.  Perspectives  on 
biotechnological methods with respect to marine drug development are also discussed. 
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1. Introduction 
Marine sponges (phylum Porifera) are among the oldest multicellular invertebrate organisms [1] 
exhibiting a wide variety of colors and shapes. About 8,000 species of sponges, inhabiting different 
marine and freshwater ecosystems have been described to date [2]. Marine sponges are a rich source of 
potent natural products, some of which are considered as highly significant lead compounds for drug 
development. Most of these are secondary metabolites produced by the sponges [3] which may be 
produced to defend themselves against pathogenic bacteria, algae, fungi and other potential predators; 
a system they have developed during the process of evolution throughout thousands of years. More 
than  5,300  different  natural  compounds  have  been  discovered  from  sponges  and  their  associated 
microorganisms, and every year several hundred new compounds are being added [4]. 
Antiviral compounds are currently of particular interest since viral diseases (e.g., HIV, H1N1, HSV, 
etc.) have become major human health problems in recent decades. The ability of a virus to rapidly 
evolve and develop resistance to existing pharmaceuticals calls for continuing development of new 
antiviral drugs. Several lead antiviral compounds have been isolated from marine sponges, and there 
has been a consistent effort to identify new compounds.  
The nucleosides  spongothymidine and spongouridine were the first  compounds isolated from  a 
marine sponge (Tethya crypta) [5,6] which further led to the synthesis of Ara-C, an anticancer agent 
and Ara-A, the first antiviral drug. Ara-A inhibits viral DNA synthesis by conversion into adenine 
arabinoside triphosphate which inhibits viral DNA polymerase and DNA synthesis of herpes, vaccinica 
and varicella zoster viruses. It has been used clinically for treatment of herpes virus infection. Ara-A 
was the only sponge derived compound which was approved by the US FDA as an antiviral drug, 
although its marketing was later stopped as it was found to be less efficient and more toxic than the 
newer drug acyclovir (Zovirax) [7,8]. In addition to nucleosides, marine sponges are also the source of 
many  alkaloids,  sterols,  terpenes,  peptides,  fatty  acids,  peroxides,  etc.  exhibiting  the  remarkable 
chemical diversity of compounds found in these organisms [9].  
Several  other  sponge  derived  antiviral  compounds  are  in  preclinical/clinical  trials  for  various 
diseases. However significant problems associated with these compounds have been a major limitation 
in  the  drug  development  and  approval  process.  This  is  primarily  due  to  the  many  technological 
challenges in detecting, isolating, characterizing, and scaling up production of bioactive compounds 
from marine sponges. To solve the critical supply problem, several efforts are being made in sponge 
farming,  metagenomics  and  microbial  cultivation,  which  are  discussed  below.  Here  we  focus  on 
existing or promising antiviral lead compounds from marine sponges which may have the potential to 
be future drugs.  
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2. Antiviral Lead Compounds 
2.1. Nucleosides 
2.1.1. Vidarabine or Ara-A 
In 1950, Bergmann et al. [6] isolated from the Caribbean sponge Tethya crypta (Tethylidae) the 
nucleosides spongothymidine and spongouridine, which contained an arabinose sugar rather than the 
more common ribose sugar  found in these nucleosides. Vidarabine or Ara-A is a synthetic analogue of 
spongouridine  with  improved  antiviral  activity.  The  antiviral  activity  of  adenine  arabinoside 
(vidarabine, Ara-A, Figure 1) was first described by Privat de Garilhe and De Rudder in 1964 [10]. 
The  work  of  Whitley  in  1976  further  confirmed  the  clinical  usefulness  of  the  compound  in  the 
treatment of herpes encephalitis and the other herpes infections that occasionally occur in newborns 
[11]. It was the first nucleoside antiviral to be licensed for the treatment of systematic herpes virus 
infection and one of the three marine-derived drugs currently approved by the FDA in the United 
States [12], however the marketing of the drug has been discontinued because the availability of newer 
and better antiviral agents on the market.  
Figure 1. Structure of Ara-A. 
 
 
 
 
 
 
Despite  its  proven  ability  as  a  therapeutic  agent  which  is  active  against  a  variety  of  viruses, 
vidarabine has some significant limitations. It is readily metabolized by adenosine deaminase (ADA) 
to  arabinofuranosyl  hypoxanthine  (ara-H),  which  is  10-fold  less  potent  [13,14]  and  has  low 
lipophilicity  and  thus  low  intestinal  membrane  permeability.  It  is  also  poorly  soluble  in  aqueous 
solutions  and  has  low  intramuscular  absorption,  requires  large  fluid  volumes  for  intravenous 
administration, and must be given over prolonged periods (8 to 12 h) [15] to obtain therapeutic effects. 
Later acyclovir (Zovirax) was found to be a better drug than vidarabine for the treatment of herpes 
virus infections [7,8] however vidarabine was reported to be capable of inhibiting acyclovir-resistant 
HSV and VZV (varicella-zoster virus) [16,17]. Vidarabine is an inhibitor of viral DNA synthesis [18]. 
Adenine arabinoside (vidarabine) is converted into adenine arabinoside triphosphate (ara-ATP) in vivo 
[19] by kinases encoded by viruses, which in turn inhibit viral DNA polymerase and hence DNA 
synthesis of herpes, vaccinia and varicella zoster viruses [12,20]. Another study found that vidarabine 
is incorporated into RNA as well as DNA, leading to another possible mechanism of action of the 
drug. It was observed that vidarabine inhibited the initial RNA polyadenylation reaction catalyzed by 
chromatin-bound poly (A) polymerase [21]. It was also recently reported that vidarabine was 3–5 fold Mar. Drugs 2010, 8                       
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more  active  in  plaque  reduction  assays  against  vaccinia  and  cowpox  viruses  than  was  cidofovir 
(Vistide) [22].  
Stereocontrolled  synthesis  of  vidarabine  [23]  and  several  analogues/derivatives  with  antiviral 
activity has been described [24–26]. Its biosynthesis from Streptomyces antibioticus has also been 
reported [27]. 
2.1.2. Mycalamide A, Mycalamide B 
Perry et al. [28] first reported the isolation and in vitro antiviral activity of mycalamide A and 
mycalamide  B  (Figure  2)  from  a  New  Zealand  sponge  of  the  genus  Mycale  in  1988  and  1990, 
respectively. The crude extract containing 2% mycalamide A was found to be active against A59 
corona virus. After treatment with crude extract at 0.1 mg/kg, mice infected with virus survived for 14 
days, however the mice infected with virus died within eight days. Mycalamide A also inhibited the 
Herpes simplex type I and Polio type I viruses at a concentration of 5 ng/disc. Mycalamide B was 
found to be more potent than mycalamide A, which was active at a concentration of 1–2 ng/disc [29]. 
Examining  the  mechanisms  involved  in  the  actions  of  these  compounds,  Burres  and  Clement 
discovered the inhibition of protein synthesis and translation of RNA into protein in a cell-free lysate 
of rabbit reticulocytes [30]. A new study also described the binding of mycalamide A to the E site of 
the large ribosomal subunit of Haloarcula
 marismortui and inhibition of protein synthesis [31]. This 
property of protein synthesis inhibition may be attributed to their biological activity as antiviral agents. 
Several studies regarding the total synthesis of mycalamides have been published [32–35]. Four 
analogues  of  mycalamide  A  have  recently  been  reported  [36]  to  bind  the  nucleoprotein  (NP)  of 
influenza virus and inhibit its multiplication. It has also shown experimentally that these compounds 
might bind to the N-terminal 13-amino acid region of NP which mediates the nuclear transport of NP 
and its binding to viral RNA, and hence may inhibit viral replication [36]. 
Figure 2. Structures of mycalamide A and B. 
 
2.2. Sesquiterpene Hydroquinones 
Avarol 
Avarol, a sesquiterpenoid hydroquinone with a rearranged drimane skeleton, was first isolated from 
the  marine  sponge  Disidea  avara  in  1974  [37].  The  chemical  structure  of  avarol  (Figure  3)  was Mar. Drugs 2010, 8                       
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established by standard analytical methods and chemical degradation [38] and by its stereocontrolled 
total synthesis [39].  
Figure 3. Structure of avarol. 
 
The compound showed a dose-dependent inhibitory effect on the replication of the etiologic agent 
of  acquired  immune  deficiency  syndrome  (AIDS)  and  human  T-lymphotropic  retrovirus  
(HTLV  III)/lymphadenopathy-associated  virus  in  human  H9  cells  in  vitro  at  a  concentration  of  
0.1 µg/mL [40]. The study suggested that the mechanism involved blocking the expression of the p24 
and  p17  gag  proteins  of  HTLV-III  in  H9  cells  after  virus  infection,  and  hence  blocking  viral 
replication. Studies dating back to 1988 showed that the antiviral effects of avarol were due to an 
increase in intracellular levels of superoxide radicals such as superoxide dismutases and of glutathione 
peroxidase [41]. The effects of avarol were further elucidated and it was found that  it completely 
blocks the synthesis of glutamine transfer tRNA, which is crucial for synthesis of a viral protease 
required for viral proliferation [42–44]. Other important biological targets inhibited by avarol or its 
derivatives include reverse transcriptase [45] which plays a key role in early stages of viral infection, 
inhibition  of  cyclooxygenase  and  5’-lipoxygenase,  thus  reducing  the  levels  of  leukotriene  B4  and 
prostaglandin E2 in vitro in HIV-1 infected monocytes [46], and modulating the expression of genes in 
HIV-infected cells [88].  
The anti-viral activity of avarone [47], a structurally similar compound also from the marine sponge 
Disidea  avara,  and  its  derivatives  [48]  has  also  been  reported.  Several  new  derivatives  of  avarol 
showing antiviral activities have also been extracted from the Red Sea sponge Dysidea cinerea [49]. 
The first enantioselective total synthesis of avarol was reported by Ling et al. [50]. In another attempt, 
the primmorph model (in vitro culture of sponge cells) was used as a model system to produce avarol 
in the laboratory [51]. The cell culture and gene cluster approaches used for sustainable production of 
avarol have also been reviewed [52]. 
2.3. Cyclic Depsipeptides 
2.3.1. Papuamide A, B, C, and D 
The  anti-HIV  and  cytotoxic  cyclic  depsipeptides,  papuamides,  were  isolated  from  the  sponges 
Theonella mirabilis and Theonella swinhoei that were collected along the north coast of Papua New 
Guinea [53]. Two groups from the National Cancer Institute and the University of British Columbia 
independently reported the isolation of papuamides A and B from T. mirabilis and papuamides A, B, 
C, and D from T. swinhoei, respectively (Figure 4).  Mar. Drugs 2010, 8                       
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Figure 4. Structures of Papuamide A, B, C and D. 
 
 
 
Extensive NMR analysis confirmed the presence of different amino acid residues, including alanine, 
threonine,  two  glycine  residues,  homoproline,  N-methylthreonine,  3-methoxyalanine,  β-methoxy-
tyrosine, 3-hydroxyleucine, 3,4-dimethylglutamine, 2,3-diaminobutanoic acid and an amide linked 2,3 
dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid [54]. Papuamides A and B have been evaluated 
for their anti-HIV activity in cell based assays in CEM-SS T-cell cultures, and found to be highly 
potent with an effective concentration of3.6 ng/mL [54]. Activities for both compounds were found to 
be virtually identical. 
Detailed mechanistic studies for the anti-HIV activity of papuamides A and B have been performed 
by Andjelic et al. [55]. Inhibition of viral entry into cells is shown to be independent of CD4, gp120, 
chemokine co-receptors and gp41, key proteins which are involved in the process of viral entry and are 
the targets of most of the FDA approved inhibitors of this process [56]. The mechanism of a direct 
interaction of papuamide A with the virus has been proposed witha membrane targeting mechanism 
believed to be responsible for the virucidal activity of the compound [55].A similar type of mechanism Mar. Drugs 2010, 8                       
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has been proposed for an antifungal sterol dependent lipopeptide [57]. Papuamide B also inhibited 
viral  entry  at  a  concentration  of  710  nM,  with  the  proposed  mechanism  of  targeting 
phosphatidylserine, a phospholipid present on the viral membrane. Papuamides C and D were found to 
be  less  potent  with  30%  and  55%  inhibition  at  a  concentration  of  40  and  20  fold  higher  than 
papuamides A and B. In a recent study Xie et al. reported the total synthesis of papuamide B [54].  
2.3.2. Microspinosamide 
Isolation of microspinosamide, a cyclic depsipeptide (Figure 5), from an Indonesian collection of 
the sponge Sidonops microspinosa was reported in 2001 [58]. Microspinosamide contained 13 amino 
acid  residues  including  alanine,  tryptophan,  arginine,  threonine,  aspartate,  valine,  two  prolines,  
tert-leucine,  β-methylisoleucine,  N-methylglutamine,  cysteic  acid  and  a  new  residue,  β-hydroxy-p-
bromo-phenylalanine. The Anti-HIV activity of crude extract of S. microspinosa was first discovered 
during the National Cancer Institute’s primary anti-HIV screening [59]. Both aqueous and organic 
extracts  of  S.  microspinosa  exhibited  anti-HIV  activity.  Microspinosamide  was  also  evaluated  for  
anti-HIV  activity  in  a  cell  based  in  vitro  assay  and  found  to  be  effective  at  a  concentration  of  
0.2 µg/mL in CEM-SS arget cells. Other cyclic depsipeptides from sponges with anti-HIV activity 
have also been reported [53,60,61]. 
Figure 5. Structure of microspinosamide. 
 
2.4. Alkaloids 
2.4.1. 4-Methylaaptamine 
Isolation of the alkaloid 4-methylaaptamine (Figure 6) from the marine sponge Aaptos sp. (collected 
in Abrolhos, Bahia, Brazil) and the preliminary activity of its crude extract to inhibit 76% of HSV-1 
replication in Vero cells at a concentration of 2.4 µg/mL was first reported by Coutinho et al. [62]. 
Another study confirmed the anti-HSV-1 activity of 4-methylaaptamine with an EC50 of 2.4 µM [63], 
which is even more potent than acyclovir, which has an EC50 of 8.6 µM [62]. 4-Methylaaptamine was 
found to inhibit HSV-1-infection in Vero cells even 4 h after infection, suggesting the inhibition of 
initial  events  during  HSV-1  replication.  Apparently  the  compound  could  inhibit  expression  of  an  Mar. Drugs 2010, 8                       
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HSV-1 immediate-early protein, ICP27, which regulates splicing, termination, and nuclear export of 
viral transcripts thus preventing viral replication [63]. 
Synthetic  transformation  of  methylaaptamine,  which  was  first  isolated  by  Nakamura  and  
co-workers [64],  into  4-methylaaptamine  has  also  been  reported [65].  
9-O-4-Ethylbenzoylisoaaptamine,  a  novel  derivative  of  isoaaptamine  also  displays  potent  activity 
against HIV-1 with an EC50 of 0.47 µg/mL [66]. 
Figure 6. Structure of 4-methylaaptamine. 
 
2.4.2. Dragmacidin F 
Cutignano et al. reported the isolation of a new bromoindole alkaloid, dragmacidin F (Figure 7), 
from  a  marine  sponge  of  the  genus  Halicortex  collected  off  the  southern  coast  of  Ustica  Island  
(Italy) [67].  
Figure 7. Structure of Dragmacidin F. 
 
The compound demonstrated in vitro antiviral activity against HSV-1 and HIV-1 with an EC50 of 
96 μM and EC50 of 0.9 μM respectively and hence is most likely responsible for the antiviral property 
exhibited  by  Halicortex  extracts.  The  compound  has  an  unprecedented  carbon  skeleton  that  is 
presumed to be derived biosynthetically from dragmacidin D by the cyclization of its partially oxidized 
form [67]. Total synthesis of (+)-dragmacidin F has been described by Garg et al. [68]. 
2.4.3. Manzamine A 
Manzamine A (Figure 8) was isolated from Haliclona sp. Found in waters near Okinawa (Japan) by 
Sakai  and  Higa  in  their  quest  to  find  antitumor  compounds  from  marine  organisms  [69].  The 
manzamine class of alkaloids has unique complex polycyclic ring systems coupled with a β-carboline 
moiety and has been reported to have a diverse range of bioactivities, including antimicrobial [70,71], 
antiparasitic  [72],  antipesticidal  [73],  and  anti-HIV-1  and  activity  against  AIDS  opportunistic 
infections [74]. Isolation of manzamine A from the sponge Pachypellina sp. (Porifera, Demospongia, Mar. Drugs 2010, 8                       
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Petrosida, Oceanapiidae) collected at Manado Bay, Sulawesi, Indonesia has also been described [75]. 
The same study reported the first anti HSV-II activity of this compound with a minimal effective 
concentration of 0.05 µg/mL. Isolation of manzamine A has also been reported from other species of 
marine  sponges  [76–78].  Enantioselective  total  synthesis  of  manzamine  A  has  been  described  by 
Humphrey et al. [79]. 
Figure 8. Structure of manzamine A. 
 
A  more  recent  study  describes  the  isolation  of  manzamine  A  from  an  undescribed  sponge  of  
the  genusAcanthostrongylophora  from  Manado  Bay,  Indonesia;  and  its  key  oral  and  intravenous 
pharmacokinetic  properties  in  rats  have  also  been  reported  [80].  This  study,  which  was  the  first 
published information regarding the pharmacokinetic properties of manzamine A, indicated that the 
compound  has  a  low  metabolic  clearance,  a  reasonably  long  pharmacokinetic  half-life,  and  good 
absolute oral bioavailability, making it a promising potential lead for further preclinical assessment 
and  possible  development.  This  study  also  reported  the  anti-HIV-1  activity  of  manzamine  A,  
8-hydroxymanzamine A, 6-deoxymanzamine X, and neokauluamine with EC50 of 4.2, 0.6, 1.6, and  
2.3 µM, respectively. 
2.5. Phenolic Macrolides 
Hamigeran B 
This compound (Figure 9) was isolated from the marine sponge Hamigera tarangaensis (family 
Anchinoidae) from the Hen and Chicken Islands in New Zealand and showed 100% in vitro virus 
inhibition against both the herpes and polio virus with only slight cytotoxicity at a concentration of  
132 µg per disk [51]. Syntheses of hamigeran B have been reported by several groups 1 [81–83]. 
Figure 9. Structure of hamigeran B. 
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3. Discussion 
A total of 40 compounds have been officially approved for clinical use in the treatment of various 
viral ailments and at least half of them are used for the treatment of HIV infection [84]. Most of the 
sponge-derived compounds have also been screened for anti-HIV activity, showing the interest and 
potential importance of this field. This has led to the discovery of many compounds with anti-HIV 
activity,  such  as  avarol,  microspinosamide,  papuamides  A–D  etc.  Although  many  antiviral  lead 
compounds have been derived from sponges, none of them has yet been approved as a drug (except 
Ara-A which is no longer in use). One of the reasons for this is the difficulty in obtaining a sustainable 
supply  of  these  complex  molecules  for  pre-clinical  and  clinical  trials  [85].  Most  of  the 
pharmaceutically  interesting  compounds  found  in  sponges  are  present  in  minute  amounts.  For 
example, in order to obtain even 300 mg of halichondrins, a potent cytostatic polyketide of sponge 
origin, 1 metric ton of the sponge Lissodendoryx sp. must be extracted [86]. In addition, it is difficult 
to chemically synthesize most of these compounds due to their highly complex structures. In addition, 
the very long drug development process [87] makes this problem even more challenging. It is clear that 
such a large amount of biomass of marine sponges cannot be harvested from nature, and in the event 
that  it  were  it  would  put  these  species  at  risk  of  extinction.  More  environmentally  friendly  and 
economically feasible strategies are clearly needed. Mariculture of sponges for large scale production 
of these compounds is an option but insufficient knowledge of the conditions and specific parameters 
for the growth and cultivation of sponges in the laboratory are the limiting factors. Culturing cells and 
primmorphs for production of metabolites may be feasible in the future but at present this technique is 
unable to produce large amount of biomass [88]. 
A growing body of evidence suggests that marine natural products may be the products of bacterial 
symbionts of sponges [89,90]. The Faulkner group demonstrated for the first time that natural products 
from sponges could be of bacterial origin [91]. Microorganisms associated with sponges have been 
characterized into 14 different phyla and their diversity and biotechnological importance have been 
reviewed [92]. Isolation and cultivation of sponge-associated microorganisms (microbial fermentation) 
producing  the  bioactive  natural  products  is  also  another  option  for  the  large  scale  production  of 
compounds of interest [93,94]. The success of this strategy depends on many factors. The majority of 
sponge  associated  microorganisms  are  difficult  to  culture  [95,96].  Improved  culturing  of  sponge 
associated  microorganisms  by  supplementing  the  media  with  sponge  extract  [97]  or  catalase  and 
sodium pyruvate [98] has been reported, but the proportion of total cultured bacteria has remained low. 
Only 0.06 and 0.1% of total bacteria could be cultured from the sponges Candidaspongia flabellate 
[99] and Rhopaloeides odorabile [97]. Furthermore, microorganisms isolated from sponges may not 
necessarily produce the same compound due to the requirement of intermediate compound/s from the 
host. Some bacteria also stop producing the compound of interest after a certain time on artificial 
media, which may be caused by a number of genetic factors linked to lack of selective pressure in 
culture [100]. To develop successful sponge culturing methods it is essential to understand the biology 
and  natural  living  conditions  of  the  sponges  affecting  growth  and  metabolite  production.  Various 
methods  to  culture sponges and sponge symbionts  have been reviewed previously [101,102].  The 
attempts to develop and grow in vitro cell lines from sponges from metabolite production have also 
been reported [103]. Mar. Drugs 2010, 8                       
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Metagenomics is another strategy that has been used successfully to identify the biosynthetic origin 
of natural products. This procedure involves the genomic analysis of the total DNA in an organism and 
its symbionts. In the past few years metagenomics has emerged as a potential solution for genetic 
characterization of unculturable bacteria associated with marine sponges [104]. The method involves 
direct extraction and cloning of DNA from a group of bacteria and its genomic sequencing [105]. 
Initial efforts included the identification and isolation of gene clusters responsible for production of 
secondary metabolites involved in biosynthetic pathways, such as polyketide synthase (PKS) gene 
clusters [106,107]. Another study reported the cloning of chondramide biosynthesis cluster from C. 
crocatus, a myxobacterium [108]. The metagenomic approach was also employed for characterizing 
sponge-specific  candidate  phylum  ―Poribacteria‖  [109,110]  and  a  new  molybdenum-containing 
oxidoreductase and transmembrane proteins were identified [110]. The gene clusters identified using 
metagenomics approach is a step forward towards solving the problem of mass production of relevant 
natural products which further depends on the expression of the isolated gene clusters in relevant host. 
Heterologous  expression  vectors  have  been  used  to  express  the  PKS  biosynthetic  clusters  in 
Pseudomonas  putida  [111,112].  Other  examples  of  expression  hosts  include  E.  coli  [111–115], 
Myxobacteria and Streptomyces [116,117] used for expression of various biosynthetic pathways. Long 
et al. [118] applied the expression based techniques to identify expressing clones. The isolation of 
compounds from marine metagenomes is successful to a limited extent but this technology has been 
effectively  employed  on  soil  metagenomes  where  several  antibiotics  have  been  isolated  using 
metagenomic  approaches  [119–122].  Although  these  studies  demonstrate  the  success  achieved  by 
using the metagenomics approach there are still some technological issues related to this approach 
which must be overcome. Studies have provided compelling evidences that natural products known as 
polyketides are structurally similar in sponges and symbiont bacteria [2,123] . It has been made clear 
that these bacteria are the key producers of polyketides [124,125]. The complexity of the genomes of 
the group of organisms makes it very difficult to identify the target genome, and is further complicated 
by the use of inappropriate host organisms for cloning and expression [105,126] as well as the large 
size of the gene clusters [127]. The obstacles are manifold since sponges play host to a wide diversity 
of  organisms  such  as  bacteria,  fungi,  protists  etc  [128]  resulting  in  a  complex  community.  The 
expression of such complex metagenome will not be feasible in simple expression systems such as E. 
coli. The complex expression systems are needed to achieve the success in case of sponges [104]. To 
overcome the challenges associated with successful implementation of metagenomics approach, new 
methods have been developed and tested recently. One possible future direction could be to perform 
sequence based screens in order to identify enzymes that have been shown to be involved in the 
synthesis of anti-viral compounds. This strategy has been successfully developed and implicated to 
known  polyketide  synthase  genes  in  an  effort  to  identify  new  polyketides  [129].  Other  recently 
developed phylogenetic approaches can be applied to study the structure and function of biosynthetic 
enzymes  as  well  as  to  isolate  target  gene  clusters  [130].  The  metagenomic  libraries  can  also  be 
screened for antiviral activities by tailoring the methodologies previously used to identify natural-
product clusters using genome sequence tags (GSTs). GSTs are the parts of the genes that can be used 
as probes to screen for similar genes in a clonal library. Any clone containing a GST can be a potential 
candidate for screening of novel natural-product gene clusters. This approach has been utilized to 
identify more than 450 natural-product clusters [131]. Mar. Drugs 2010, 8                       
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4. Conclusions 
The literature regarding antiviral compounds from sponges shows the significance of marine natural 
products in the drug discovery and development process. With advancement of technologies a new 
generation of potent and effective antiviral agents may be obtained from these sources. Sequence based 
screens, metagenomic clonal library screening using GSTs and other phylogenetic approaches could 
provide a new future dimension in search for antiviral natural compounds from sponges. The successes 
in  metagenomics  coupled  with  heterologous  expression  and  high  throughput  microbial  cultivation 
techniques could pave the way for commercial production of such compounds in the future, greatly 
facilitating their analysis and commercialization.  
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